West Pharmaceutical Services Inc (WST)
SobrevaloradaFundamental
66
Precio
$370.76
Capitalización Bursátil
$26.44B
Parte 1 · Cuánto vale la empresa
Resumen
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$3.33B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$565M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$469M
Patrimonio Neto Total
$3.18B
Pasivo Total
$1.09B
Ratio de Liquidez
2.82
Cobertura de Intereses
151.20
Deuda/EBITDA
0.42
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$258.38
Precio Actual
$370.76
Margen de Seguridad
-43.5%
Rango de Valor Justo
$167.95 - $348.82
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
47.47
ROE
15.5%
Ratio P/B
8.73
P/FCF
59.72
Margen Bruto
36.8%
ROIC
15.6%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
15.6%
WACC
10.7%
ROIC − WACC
+4.9 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (21)
- EPS shows upward trend
- EPS CAGR 6.05%
- Price CAGR 15.10%
- ROIC 15.6%
- Gross Margin 36.8%
- Debt/Equity ratio
- Operating Margin 20.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 18.5%
- Revenue Growth 5Y 7.4%
- Analyst Consensus 91% Buy
- Earnings Surprise avg 16.0%
- Earnings Quality (OCF/NI) 1.17
- Share Dilution -1.3%
- Net Margin Trend 17.0% vs 16.5%
- Piotroski F-Score 7/9
Fallido (6)
- P/FCF 59.72
- P/B Ratio 8.73
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 5.59
No disponible (1)
- Dividend Payout NaN%
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 56 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 60 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 45 |
| Mr. Michel Lagarde | President, CEO & Director | 50 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 46 |
| Dr. Devesh Mathur | Senior VP & CTO | - |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | - |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 60 |
| Ms. Michele Polinsky | Vice President of Global Communications | - |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 55 |
Riesgo de Auditoría
10
Riesgo del Consejo
9
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-17
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-23
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-07-23
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for WST, sourced from Markets Gazette.
- 4/23/2026POSITIVEWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.
via Markets Gazette